Orbimed Advisors LLC Fate Therapeutics Inc Transaction History
Orbimed Advisors LLC
- $3.69 Billion
- Q4 2024
A detailed history of Orbimed Advisors LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 1,680,580 shares of FATE stock, worth $2.39 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,680,580
Previous 1,680,580
-0.0%
Holding current value
$2.39 Million
Previous $5.88 Million
52.87%
% of portfolio
0.08%
Previous 0.14%
Shares
3 transactions
Others Institutions Holding FATE
# of Institutions
167Shares Held
101MCall Options Held
41.3KPut Options Held
15.9K-
Redmile Group, LLC San Francisco, CA12.9MShares$18.3 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$14.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$14.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$6.87 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$6.22 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $138M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...